Mereo BioPharma (NASDAQ: MREO) sees cash lasting to mid-2027 operations

Rhea-AI Filing Summary

Mereo BioPharma Group plc updated its liquidity outlook and provided new investor materials. The company reported cash and cash equivalents of $41 million as of December 31, 2025, which it now expects will fund operations to mid-2027, extending its projected cash runway. Mereo also issued a corporate update press release and posted an investor presentation for use at the J.P. Morgan Healthcare Conference and other meetings, which are furnished as exhibits and not deemed filed under U.S. securities laws.

Insights

Biotech equity analyst

Mereo extends its cash runway to mid-2027 on $41M cash.

Mereo BioPharma Group plc disclosed that cash and cash equivalents were $41 million as of December 31, 2025. Based on current plans, management now expects this balance to fund operations to mid-2027, giving roughly an additional year and a half of visibility from that date.

This update helps frame funding needs around the company’s clinical and partnering strategy, but it does not change capital structure or announce new financing. The actual duration of the runway will depend on spending levels and any business milestones described in its broader disclosures.

The same report notes a new corporate update press release and an investor presentation for the J.P. Morgan Healthcare Conference, suggesting more detail on programs and priorities is available there. Subsequent periodic reports may further refine cash expectations as development and collaboration plans evolve.

0001719714truefalseX000-00000000001719714dei:AdrMember2026-01-122026-01-120001719714us-gaap:CommonStockMember2026-01-122026-01-1200017197142026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

MEREO BIOPHARMA GROUP PLC

(Exact name of registrant as specified in its charter)

England and Wales		001-38452		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4th Floor, One Cavendish Place,

London, W1G 0QF

United Kingdom

(Address of principal executive offices, including zip code)

+44-333-023-7300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share		MREO		The Nasdaq Stock Market LLC
Ordinary Shares, nominal value £0.003 per share*		*		The Nasdaq Stock Market LLC

*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Mereo BioPharma Group plc (the “Company”) issued a press release providing a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The Company has also made available on its website a presentation for use at the J.P. Morgan Healthcare Conference and future conferences and meetings with investors, analysts and others (the “Presentation”). A copy of the Presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

The information contained in this Item 7.01, including Exhibit 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

Item 8.01 Other Events.

On January 12, 2026, the Company updated its previous cash runway guidance. As of December 31, 2025, cash and cash equivalents were approximately $41 million, which are expected to fund operations to mid-2027.

Forward Looking Statements

This Current Report on Form 8-K contains “forward-looking statements.” All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of the Company’s operations or operating results. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on Mereo’s current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on Mereo. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting Mereo will be those that it anticipates. All of Mereo’s forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and assumptions that could cause actual results to differ materially from Mereo’s historical experience and its present expectations or projections. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process; Mereo’s reliance on third parties to conduct and provide funding for its clinical trials; Mereo’s dependence on enrollment of patients in its clinical trials; and Mereo’s dependence on its key executives. You should carefully consider the foregoing factors and the other risks and uncertainties that affect Mereo’s business, including those described in the “Risk Factors” section of its latest Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Mereo’s subsequent filings with the Securities and Exchange Commission. Mereo wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Mereo undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

Item 9.01 Financial Statements and Exhibits.

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:

(d) Exhibits

Exhibit No.	Description of Exhibit
99.1	Press Release, dated January 12, 2026.
99.2	Presentation, dated January 12, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	MEREO BIOPHARMA GROUP PLC
Date: January 12, 2026	By:	/s/ Christine Fox
		Name:	Christine Fox
		Title:	Chief Financial Officer

FAQ

What cash position did Mereo BioPharma (MREO) report?

Mereo BioPharma reported cash and cash equivalents of $41 million as of December 31, 2025, providing the basis for its updated cash runway guidance.

How long does Mereo BioPharma expect its cash to last?

The company now expects its $41 million of cash and cash equivalents as of December 31, 2025 to fund operations to mid-2027.

What new investor materials did Mereo BioPharma release with this update?

Mereo BioPharma furnished a corporate update press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) prepared for the J.P. Morgan Healthcare Conference and other meetings.

Are the new Mereo BioPharma materials considered filed with the SEC?

No. The information in Item 7.01, including Exhibits 99.1 and 99.2, is furnished, not filed, and is not subject to liability under Section 18 of the Exchange Act.

What risks does Mereo BioPharma highlight alongside its forward-looking cash guidance?

The company notes risks such as clinical development uncertainties, reliance on third-party funding and trial conduct, patient enrollment challenges, and dependence on key executives, among others referenced in its risk factor disclosures.

What event date does this Mereo BioPharma update relate to?

The report states that on January 12, 2026, Mereo BioPharma issued the corporate update press release and updated its cash runway guidance.